Drugs / CD 2027
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00919763 | May → Oct 2009 | atopic eczema | Galderma R&D | Completed | No outcome recorded |
| Phase 2 | NCT00763555 | Sep 2008 → Jan 2009 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 2 | NCT00763503 | Sep → Dec 2008 | psoriasis | Galderma R&D | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD 2027 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00763555 ↗ |
| Route | Topical | “applied to 20% of BSA” NCT00763503 ↗ |